Abstract
Diabetic neuropathic foot ulcers represent a serious health care burden to patients and to society. While the management of chronic diabetic foot ulcers has improved in recent years, it remains a frustrating problem for a variety of clinicians. This review examines the scientifi c underpinnings supporting the use of becaplermin (Regranex®; Ortho-McNeil Pharmaceutical, Raritan, NJ), or recombinant human platelet-derived growth factor (rhPDGF-BB), in diabetic forefoot wounds. An emphasis is placed upon proper medical and surgical care of diabetic foot wounds, as multiple studies have demonstrated that the success of this growth factor in accelerating healing is ultimately dependent on proper ulcer care. A focus on the costeffectiveness of this form of therapy in the treatment of diabetic foot ulcers is also outlined.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-12 |
| Number of pages | 12 |
| Journal | Biologics: Targets and Therapy |
| Volume | 2 |
| Issue number | 1 |
| State | Published - Dec 1 2008 |
Keywords
- Becaplermin
- Diabetes
- Foot ulcer
- Growth factor
ASJC Scopus subject areas
- Immunology and Allergy
- Rheumatology
- Oncology
- Gastroenterology
- Pharmacology (medical)
